Get the Stockscreener App
8.07
4.89%
-0.415
Pre-market:
8.25
0.18
+2.23%
Verve Therapeutics Inc Stock (VERV) Latest News
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Verve Therapeutics, Inc. (VERV) Investigation - ACCESS Newswire
Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 10.4% HigherShould You Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading Down 4.9%Time to Sell? - MarketBeat
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.7%Time to Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Shares Gap UpHere's What Happened - MarketBeat
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence - TipRanks
Verve Therapeutics Inc [VERV] stock for 3,130 USD was sold by Dorval Allison - Knox Daily
Perhaps timely catching Verve Therapeutics Inc (VERV) would be a good idea - SETE News
Verve Therapeutics (NASDAQ:VERV) Shares Down 5.7%What's Next? - MarketBeat
Verve Investor Drops Class Suit Over Halted Clinical Trial (1) - Bloomberg Law
France Programmatic Ad Seller Quality Rankings Q4 2024: Outbrain Tops Pixalate’s Web Seller Trust Index; Verve No. 1 on Mobile - GlobeNewswire Inc.
STATE STREET CORP Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Verve Therapeutics' Market Cap Up US$69m Following Year Of Insider Stock Buying - Simply Wall St
Is Now The Time To Buy Verve Therapeutics Inc (NASDAQ: VERV) Stock? - Stocks Register
Is Verve Therapeutics Inc (VERV) a threat to investors? - US Post News
China Universal Asset Management Co. Ltd. Buys 1,676 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - ETF Daily News
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Awards $1M+ in Equity Incentives to Accelerate Growth Strategy - StockTitan
Nisa Investment Advisors LLC Raises Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 5.6% HigherHere's Why - MarketBeat
(VERV) Proactive Strategies - Stock Traders Daily
Millennium Management LLC Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PR Newswire
Verve Therapeutics (NASDAQ:VERV) Trading Down 8.2%What's Next? - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLC - Defense World
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Verve's Next Move: CEO Kathiresan Takes Center Stage at Elite Biotech Summit - StockTitan
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Yahoo Finance
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading Up 6.1%Should You Buy? - MarketBeat
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? - Yahoo Finance
Brokers Offer Predictions for VERV FY2025 Earnings - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Forecasts VERV FY2025 Earnings - MarketBeat
(VERV) Trading Advice - Stock Traders Daily
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading 8.6% HigherTime to Buy? - MarketBeat
GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Raised by Barclays PLC - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World
Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - The Manila Times
0.79%
3.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):